Novel perspectives on arrhythmia-induced cardiomyopathy

Pathophysiology, clinical manifestations and an update on invasive management strategies

Domenico G. Della Rocca, Luca Santini, Giovanni B. Forleo, Aurora Sanniti, Armando Del Prete, Carlo Lavalle, Luigi Di Biase, Andrea Natale, Francesco Romeo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Arrhythmia-induced cardiomyopathy is a partially or completely reversible form of myocardial dysfunction due to sustained supraventricular and ventricular arrhythmias. Asynchrony, rapid cardiac rates and rhythm irregularities are the main factors involved in the development of the disease. The reversible nature of arrhythmia-induced cardiac dysfunction allows only for a retrospective diagnosis of the disease once cardiac function is restored following heart rate control. A high level of suspicion is needed to make a diagnosis at an early stage and prevent further progression of the disease. Although reversible, arrhythmia-induced cellular and molecular changes may remain, increasing the risk for sudden death even when normal ejection fraction is restored as well as causing rapid deterioration of cardiac function and development of heart failure symptoms if arrhythmia recurs. Appropriate management based on a combination of pharmacologic and nonpharmacologic strategies to achieve rate control and prevent arrhythmia recurrence is pivotal to avoid further cardiac function deterioration and to control symptoms, significantly reducing the risk of heart failure and sudden cardiac death.

Original languageEnglish (US)
Pages (from-to)135-141
Number of pages7
JournalCardiology in Review
Volume23
Issue number3
DOIs
StatePublished - Jul 9 2015

Fingerprint

Cardiomyopathies
Cardiac Arrhythmias
Heart Failure
Sudden Cardiac Death
Sudden Death
Disease Progression
Heart Diseases
Heart Rate
Recurrence

Keywords

  • arrhythmia-induced cardiomyopathy
  • atrial fibrillation
  • premature ventricular complex
  • reversible cardiomyopathy
  • transcatheter ablation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Novel perspectives on arrhythmia-induced cardiomyopathy : Pathophysiology, clinical manifestations and an update on invasive management strategies. / Della Rocca, Domenico G.; Santini, Luca; Forleo, Giovanni B.; Sanniti, Aurora; Del Prete, Armando; Lavalle, Carlo; Di Biase, Luigi; Natale, Andrea; Romeo, Francesco.

In: Cardiology in Review, Vol. 23, No. 3, 09.07.2015, p. 135-141.

Research output: Contribution to journalArticle

Della Rocca, Domenico G. ; Santini, Luca ; Forleo, Giovanni B. ; Sanniti, Aurora ; Del Prete, Armando ; Lavalle, Carlo ; Di Biase, Luigi ; Natale, Andrea ; Romeo, Francesco. / Novel perspectives on arrhythmia-induced cardiomyopathy : Pathophysiology, clinical manifestations and an update on invasive management strategies. In: Cardiology in Review. 2015 ; Vol. 23, No. 3. pp. 135-141.
@article{f40b1f1ac3684a108c5b37befd2b1570,
title = "Novel perspectives on arrhythmia-induced cardiomyopathy: Pathophysiology, clinical manifestations and an update on invasive management strategies",
abstract = "Arrhythmia-induced cardiomyopathy is a partially or completely reversible form of myocardial dysfunction due to sustained supraventricular and ventricular arrhythmias. Asynchrony, rapid cardiac rates and rhythm irregularities are the main factors involved in the development of the disease. The reversible nature of arrhythmia-induced cardiac dysfunction allows only for a retrospective diagnosis of the disease once cardiac function is restored following heart rate control. A high level of suspicion is needed to make a diagnosis at an early stage and prevent further progression of the disease. Although reversible, arrhythmia-induced cellular and molecular changes may remain, increasing the risk for sudden death even when normal ejection fraction is restored as well as causing rapid deterioration of cardiac function and development of heart failure symptoms if arrhythmia recurs. Appropriate management based on a combination of pharmacologic and nonpharmacologic strategies to achieve rate control and prevent arrhythmia recurrence is pivotal to avoid further cardiac function deterioration and to control symptoms, significantly reducing the risk of heart failure and sudden cardiac death.",
keywords = "arrhythmia-induced cardiomyopathy, atrial fibrillation, premature ventricular complex, reversible cardiomyopathy, transcatheter ablation",
author = "{Della Rocca}, {Domenico G.} and Luca Santini and Forleo, {Giovanni B.} and Aurora Sanniti and {Del Prete}, Armando and Carlo Lavalle and {Di Biase}, Luigi and Andrea Natale and Francesco Romeo",
year = "2015",
month = "7",
day = "9",
doi = "10.1097/CRD.0000000000000040",
language = "English (US)",
volume = "23",
pages = "135--141",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Novel perspectives on arrhythmia-induced cardiomyopathy

T2 - Pathophysiology, clinical manifestations and an update on invasive management strategies

AU - Della Rocca, Domenico G.

AU - Santini, Luca

AU - Forleo, Giovanni B.

AU - Sanniti, Aurora

AU - Del Prete, Armando

AU - Lavalle, Carlo

AU - Di Biase, Luigi

AU - Natale, Andrea

AU - Romeo, Francesco

PY - 2015/7/9

Y1 - 2015/7/9

N2 - Arrhythmia-induced cardiomyopathy is a partially or completely reversible form of myocardial dysfunction due to sustained supraventricular and ventricular arrhythmias. Asynchrony, rapid cardiac rates and rhythm irregularities are the main factors involved in the development of the disease. The reversible nature of arrhythmia-induced cardiac dysfunction allows only for a retrospective diagnosis of the disease once cardiac function is restored following heart rate control. A high level of suspicion is needed to make a diagnosis at an early stage and prevent further progression of the disease. Although reversible, arrhythmia-induced cellular and molecular changes may remain, increasing the risk for sudden death even when normal ejection fraction is restored as well as causing rapid deterioration of cardiac function and development of heart failure symptoms if arrhythmia recurs. Appropriate management based on a combination of pharmacologic and nonpharmacologic strategies to achieve rate control and prevent arrhythmia recurrence is pivotal to avoid further cardiac function deterioration and to control symptoms, significantly reducing the risk of heart failure and sudden cardiac death.

AB - Arrhythmia-induced cardiomyopathy is a partially or completely reversible form of myocardial dysfunction due to sustained supraventricular and ventricular arrhythmias. Asynchrony, rapid cardiac rates and rhythm irregularities are the main factors involved in the development of the disease. The reversible nature of arrhythmia-induced cardiac dysfunction allows only for a retrospective diagnosis of the disease once cardiac function is restored following heart rate control. A high level of suspicion is needed to make a diagnosis at an early stage and prevent further progression of the disease. Although reversible, arrhythmia-induced cellular and molecular changes may remain, increasing the risk for sudden death even when normal ejection fraction is restored as well as causing rapid deterioration of cardiac function and development of heart failure symptoms if arrhythmia recurs. Appropriate management based on a combination of pharmacologic and nonpharmacologic strategies to achieve rate control and prevent arrhythmia recurrence is pivotal to avoid further cardiac function deterioration and to control symptoms, significantly reducing the risk of heart failure and sudden cardiac death.

KW - arrhythmia-induced cardiomyopathy

KW - atrial fibrillation

KW - premature ventricular complex

KW - reversible cardiomyopathy

KW - transcatheter ablation

UR - http://www.scopus.com/inward/record.url?scp=84936891019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936891019&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000040

DO - 10.1097/CRD.0000000000000040

M3 - Article

VL - 23

SP - 135

EP - 141

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -